Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 16Recruiting 9Unknown 3Terminated 1Not yet recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Classical hematology 1

Conditions

Venous Thromboembolism 1Multiple Myeloma 1

Interventions

Cyclophosphamide 241Radiotherapy 217Gemcitabine 187Cisplatin 185Carboplatin 182Docetaxel 166Bevacizumab 166Paclitaxel 144Capecitabine 142Rituximab 141pembrolizumab 140Nivolumab 126Oxaliplatin 124Dexamethasone 122Fluorouracil 113fludarabine 104Radiosurgery 101Doxorubicin 99fludarabine phosphate 97Irinotecan 96Etoposide 95Lenalidomide 93Cytarabine 92Magnetic Resonance Spectroscopy 90Radiation 89Filgrastim 89Leucovorin 88Bortezomib 86Cetuximab 80Pemetrexed 79

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × OTHER × apixaban × Clear all
NCT04106700 2021-02-15

Prophylaxis With Apixaban in Transplant Eligible Patients With Multiple Myeloma Receiving Induction Therapy With IMiDs

Instituto de Investigacion Sanitaria La Fe

Phase 2 Terminated
60 enrolled
Classical hematologyPlasma cell

Multiple Myeloma, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡